Background: The infectious human immunodeficiency virus (HIV) particle is characterized by
a conical capsid that encloses the viral RNA genome. The capsid is essential for HIV-1 …

Recent efforts by both academic and pharmaceutical researchers have focused on the HIV-1
capsid (CA) protein as a new therapeutic target. An interprotomer pocket within the hexamer …

Small molecules that bind to the viral capsid protein can be potent inhibitors of HIV infection.
Capsid-targeting drugs are predicted to exhibit high barriers to viral resistance, and ongoing …

Human immunodeficiency virus (HIV) capsid plays important roles at multiple stages of viral
replication. At the initial stages, controlled uncoating (disassembly) of the capsid ensures …

The human immunodeficiency virus type 1 (HIV-1) capsid protein is an attractive therapeutic
target, owing to its multifunctionality in virus replication and the high fitness cost of amino …

During the assembly stage of the human immunodeficiency virus (HIV) replication cycle,
several thousand copies of the viral Gag polyprotein associate at the cell membrane and …

Human immunodeficiency virus type 1 (HIV-1) infection is dependent on the proper
disassembly of the viral capsid, or “uncoating,” in target cells. The HIV-1 capsid consists of a …

Despite a high current standard of care in antiretroviral therapy for HIV, multidrug-resistant
strains continue to emerge, underscoring the need for additional novel mechanism inhibitors …

Highlights•Capsid proteins of enveloped viruses engage in multiple different protein–protein
interactions.•The capsid assembly and disassembly processes are sensitive to inhibition by …

The Human Immunodeficiency Virus type 1 (HIV-1) virion contains a conical shell, termed
capsid, encasing the viral RNA genome. After cellular entry of the virion, the capsid is …